
Mike Natter, MD
@mike_natter
Followers
34K
Following
22K
Media
2K
Statuses
6K
ARTIST. HUMANIST. DOCTOR. 🤘🏼Endocrinologist in NYC. #T1D. All posts/opinions are my own and not the views of my employer. insta: @mike.natter
New York, NY
Joined May 2015
RT @EricTopol: The mechanisms by which ultra-processed foods (UPF) drive obesity, an outstanding review article."the evidence is sufficient….
0
263
0
RT @MWeintraubMD: A fantastic talk by Dr. Jose Aleman on Weight Loss Pharmacotherapy in the Spectrum of Obesity Care at #ENDO2025
https://t….
0
4
0
RT @MWeintraubMD: The hunt for additional targets for obesity treatment is on. A novel coagonist of MC4R and GLP1 which as the potential….
0
5
0
RT @MWeintraubMD: Multiple benefits of GLP1s in reducing residual risk in those with type 1 diabetes. Excellent talk by Dr. Kaitlin Love….
0
20
0
RT @MWeintraubMD: What are the mental health outcomes in those taking GLP1s?. A recent meta-analysis shows no difference in psychiatric eff….
0
19
0
RT @MWeintraubMD: The GLP1 discontinuation rate in the real world is alarmingly high. 64% at 1 year and 84% at 2 years in those without d….
0
89
0
RT @MWeintraubMD: Early rapid weight loss with GLP1s predicts greater longer term weight loss. Rapid responders (>15% weight loss in 24 w….
0
36
0
RT @MWeintraubMD: Tirzepatide in a target emulation trial demonstrates significantly lower MACE (HR 0.8) and all cause mortality (HR 0.6) c….
0
19
0
RT @MWeintraubMD: ❗ New CagriSema Phase 3 data released. Combination cagrilintide-semaglutide after 68 weeks in patients with Type 2 Diabet….
0
6
0
RT @MWeintraubMD: The prevalence of type 2 diabetes in the young is rising, and so are the complications. 80% of individuals develop a mi….
0
28
0
RT @MWeintraubMD: There is a national shortage of endocrinologists!. The majority of the country do not have local access to endocrinologis….
0
21
0
RT @parthaskar: Since we have just crossed #StarWarsDay and we are on May 5th aka #RevengeOfThe5th 😀. A reminder of the comic book created….
0
15
0